DK0506884T3 - Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler - Google Patents

Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler

Info

Publication number
DK0506884T3
DK0506884T3 DK91903111.2T DK91903111T DK0506884T3 DK 0506884 T3 DK0506884 T3 DK 0506884T3 DK 91903111 T DK91903111 T DK 91903111T DK 0506884 T3 DK0506884 T3 DK 0506884T3
Authority
DK
Denmark
Prior art keywords
eukaryotic cells
delivering molecules
delivering
interest
molecule
Prior art date
Application number
DK91903111.2T
Other languages
English (en)
Inventor
Alan Frankel
Carl Pabo
Original Assignee
Whitehead Biomedical Inst
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst, Univ Johns Hopkins Med filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of DK0506884T3 publication Critical patent/DK0506884T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK91903111.2T 1989-12-21 1990-12-21 Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler DK0506884T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45445089A 1989-12-21 1989-12-21

Publications (1)

Publication Number Publication Date
DK0506884T3 true DK0506884T3 (da) 1996-11-04

Family

ID=23804657

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91903111.2T DK0506884T3 (da) 1989-12-21 1990-12-21 Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler

Country Status (10)

Country Link
EP (1) EP0506884B1 (da)
JP (1) JPH05505102A (da)
AT (1) ATE142266T1 (da)
AU (1) AU658818B2 (da)
CA (1) CA2071214C (da)
DE (1) DE69028412T2 (da)
DK (1) DK0506884T3 (da)
ES (1) ES2091916T3 (da)
GR (1) GR3021474T3 (da)
WO (1) WO1991009958A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
NZ239893A (en) * 1990-09-25 1993-11-25 Hoechst Japan A method for introducing a foreign dna into a cell
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
WO1993012234A1 (en) * 1991-12-13 1993-06-24 Sri International Antiviral reagents based on rna-binding proteins
ES2123062T3 (es) 1992-08-21 1999-01-01 Biogen Inc Polipeptidos de transporte derivados de la proteina tat.
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus
JP3701966B2 (ja) * 1993-01-26 2005-10-05 ウェイナー,デービッド・ビー 遺伝物質送達のための組成物および方法
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
ES2320883T3 (es) * 1993-01-26 2009-05-29 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y metodos para la administracion de material genetico.
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
JP2002502376A (ja) 1997-05-21 2002-01-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 生物学的膜を横切る輸送を増強するための組成物および方法
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6348185B1 (en) 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
KR100379578B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티-씨3 트랜스페라제 융합단백질, 이융합단백질의 발현벡터 및 티에이티-씨3 트랜스페라제를이용한 로 단백질의 생리적 기능 분석방법
KR100379577B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법
EP1401473B1 (en) 2001-02-16 2009-07-29 Cellgate Inc. Transporters comprising spaced arginine moieties
JP2003009883A (ja) * 2001-07-05 2003-01-14 Mitsubishi Pharma Corp マスト細胞の細胞死誘発剤
KR100495138B1 (ko) * 2001-07-31 2005-06-14 학교법인 한림대학교 식물세포 투과 도메인-화물분자 복합체
DE10212867B4 (de) * 2002-03-22 2005-07-21 Hans Prof. Dr. Wolf Verwendung Harnstoff-adjuvierter Polypeptide zur Diagnose, Prophylaxe und Therapie
KR100472939B1 (ko) * 2002-05-24 2005-03-18 학교법인 한림대학교 세포침투성 티에이티-피리독살 카이네이즈 융합단백질 및그 용도
WO2004009665A2 (en) 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimers as molecular translocators
KR100472937B1 (ko) * 2002-07-25 2005-03-10 학교법인 한림대학교 세포침투성 티에이티-사이토신 디아미네이즈 융합단백질및 그 용도
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
WO2006088740A2 (en) 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1
WO2006094200A2 (en) * 2005-03-03 2006-09-08 The Trustees Of Boston College Method of obtaining a desired localization for cellular imaging with the use of peptidoconjugates
US7935816B2 (en) 2007-10-25 2011-05-03 Gene Tools, Llc Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
WO2012040295A2 (en) 2010-09-22 2012-03-29 The Regents Of The University Of Colorado Therapeutic applications of smad7
EP2964774B1 (en) 2013-03-08 2020-05-06 The Regents of The University of Colorado, A Body Corporate Ptd-smad7 therapeutics
KR101835554B1 (ko) 2014-06-24 2018-04-19 서울대학교 산학협력단 C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법
US11466069B2 (en) 2017-04-28 2022-10-11 Auckland Uniservices Limited Methods of treatment and novel constructs
EP3790571B1 (en) 2018-05-03 2024-08-14 University Of Utah Research Foundation Peptides derived from oca-b for use in the treatment of autoimmune diseases and of leukemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
EP0273085A1 (en) * 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates

Also Published As

Publication number Publication date
EP0506884B1 (en) 1996-09-04
WO1991009958A3 (en) 1991-08-08
DE69028412D1 (de) 1996-10-10
DE69028412T2 (de) 1997-03-27
AU7182991A (en) 1991-07-24
ES2091916T3 (es) 1996-11-16
EP0506884A1 (en) 1992-10-07
WO1991009958A2 (en) 1991-07-11
GR3021474T3 (en) 1997-01-31
JPH05505102A (ja) 1993-08-05
AU658818B2 (en) 1995-05-04
ATE142266T1 (de) 1996-09-15
CA2071214C (en) 2006-06-06
CA2071214A1 (en) 1991-06-22

Similar Documents

Publication Publication Date Title
DK0506884T3 (da) Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
DE69431060D1 (de) Klonierte glutaminsäure-decarboxylase
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
DE69636891D1 (de) Immunstimulierende zusammensetzung und verfahren
ES2109924T3 (es) Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas.
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
NL300062I2 (nl) Osteogene middelen.
BR9507678A (pt) Construção de dna vetor de expressão recombinante célula proceso para produzir uma enzima enzima preparação de enzima uso da enzima e cultura
DK1724354T3 (da) Cirkulær DNA-molekyle med en afhængig replikationsoprindelse, fremgangsmåde til fremstilling heraf og anvendelse heraf i genterapi
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
CA2199832A1 (en) Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
NO893135D0 (no) Fremgangsmaate for fremstilling av n-2,3-butadienyl tri- og tetraaminoalkanderivater.
WO1994025590A3 (en) Trichohyalin and transglutaminase-3 and methods of using same
DK1000154T3 (da) Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering
Jones Protein synthesis in bupivacaine (Marcaine)‐treated, regenerating skeletal muscle
Dounce Nuclear Gels and Chromosomal Structure: A study of viscoelastic gel formation by isolated cell nuclei is brought to bear on the problem of how mammalian chromosomes are put together
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
WO2000043510A3 (en) Ras activator nucleic acid molecules - guanine nucleotide releasing factor grf4, polypeptides and methods of use